Skip to main content

Advertisement

SpringerLink
Log in

PET in lymphoma: what are the oncologist's needs?

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Fluorine-18 fluorodeoxyglucose positron emission tomography (PET) has a number of potential advantages for the oncologist in refining and improving the management of lymphomas. Currently the most promising appear to be in the early prediction of response to chemotherapy, evaluation of the residual mass and improved radiotherapy planning. Other important areas which require assessment are its value in refining prognostic indices at staging and its role in follow-up. The added value of the new combined PET-CT scanners requires careful evaluation in each of these settings, where combined morphological and functional information may provide optimal disease assessment. The ultimate aim is to improve the management of patients with lymphoma by identifying those patients who can be cured with minimal treatment and equally those for whom conventional treatment is doomed to failure and in whom more intensive strategies should be employed from the outset.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1.

Similar content being viewed by others

References

  1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339:1506–1514.

    Google Scholar 

  2. The International non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non Hodgkin's lymphoma. N Engl J Med 1993; 329:987.

    Google Scholar 

  3. Hoskin PJ. FDG PET in the management of lymphoma: a clinical perspective. Eur J Nucl Med 2002; 29:449–451.

    Google Scholar 

  4. Buchmann I, Reinhardt M, Elsner K, et al. 2-(Fluorine-18)fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter study. Cancer 2001; 91; 889–899.

    Google Scholar 

  5. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9:1117–1122.

    Google Scholar 

  6. Partridge S, Timothy A, O'Doherty MJ, et al. 2-Fluorine-18-fluoro-2-deoxy-d glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11:1273–1279.

    Google Scholar 

  7. Mikhael NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non Hodgkin's lymphoma—comparison with CT. Leuk Leukaemia 2000; 39:543–553.

    Google Scholar 

  8. Maisey NR, Hill ME, Webb A, et al. Are18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000; 36:200–206.

    Google Scholar 

  9. Lucraft HH. Strategies to reduce deaths from breast cancer following mantle irradiation. Clin Oncol 2000; 12:276–277.

    Google Scholar 

  10. Hoskin PJ. The price of anticancer intervention: secondary malignancies after radiotherapy. Lancet Oncol 2002; 3:577–578.

    Google Scholar 

  11. Chronowski GM, Wilder RB, Tucker S, et al. Analysis of in field control and late toxicity for adults with early stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:36–43.

    Google Scholar 

  12. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414–419.

    Google Scholar 

  13. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339:21–26.

    Google Scholar 

  14. Moody AM, Pratt J, Vaughan Hudson G, Smith P, Lamont A, Williams MV. British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease. Clin Oncol 2000; 13:262–268.

    Google Scholar 

  15. Wirth A, Wolf M, Prince HM. Current trends in the management of early stage Hodgkin's disease. Aust NZ J Med 1999; 29:535–544.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Vernon Cancer Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK

    P. J. Hoskin

Authors
  1. P. J. Hoskin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. J. Hoskin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoskin, P.J. PET in lymphoma: what are the oncologist's needs?. Eur J Nucl Med Mol Imaging 30 (Suppl 1), S37–S41 (2003). https://doi.org/10.1007/s00259-003-1158-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1158-5

Keywords

Search

Navigation